Advice
following a a full submission:
caspofungin acetate (Caspofungin) is not recommended for use within NHS Scotland.
Efficacy and safety data provided to support the possible benefits of caspofungin in the treatment of invasive aspergillosis were extremely limited, and in the form of one small, open-label, uncontrolled study. This evidence is not considered sufficiently robust to justify a recommendation for use at present.
The applicant company has since confirmed that the results of a randomised clinical trial have been published in December 2002. The SMC will provide a further recommendation on this product once an additional submission has been made and assessed.
Download detailed advice19KB (PDF)
Medicine details
- Medicine name:
- caspofungin acetate (Caspofungin)
- SMC ID:
- 30/03
- Indication:
- for the treatment of invasive aspergillosis.
- Pharmaceutical company
- MSD
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 07 March 2003